These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7127246)

  • 1. Early tumor and leukemia response to alkyllysophospholipids in a phase I study.
    Berdel WE; Schlehe H; Fink U; Emmerich B; Maubach PA; Emslander HP; Daum S; Rastetter J
    Cancer; 1982 Nov; 50(10):2011-5. PubMed ID: 7127246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
    Tan CT; Hancock CH; Mondora A; Hoffman NW
    Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
    O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M
    Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of divided-dose vinblastine in non-small cell bronchogenic carcinoma.
    Schulman P; Budman DR; Vinciguerra V; Weiselberg L; Abrams S; Degnan T
    Cancer Treat Rep; 1982 Jan; 66(1):171-2. PubMed ID: 7053253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vindesine in bronchogenic carcinoma: a phase II trial.
    Vogelzang NJ; Peterson BA; Kennedy BJ; Vosika GJ; Conroy JA
    Am J Clin Oncol; 1982 Feb; 5(1):41-4. PubMed ID: 6282107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on various parameters influencing leukemic cell destruction by alkyl-lysophospholipids.
    Andreesen R; Modolell M; Oepke GH; Common H; Löhr GW; Munder PG
    Anticancer Res; 1982; 2(1-2):95-100. PubMed ID: 7114806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
    Kantarjian HM; Beran M; O'Brien S; Robertson L; Siddik Z; Yoshida M; Yang LY; Rios MB; Keating MJ; Meyer M
    Leukemia; 1996 Mar; 10(3):396-401. PubMed ID: 8642853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phase II study of VP-16 in patients with primary bronchogenic carcinoma, with special reference to small cell carcinoma--a multi-institutional cooperative study].
    Kanda T; Oka M; Hara K; Koteda T; Ishizaki T; Ikebe A; Nakano M; Iwasaki H; Tsutsumi T; Okuno K
    Nihon Gan Chiryo Gakkai Shi; 1986 Feb; 21(1):12-8. PubMed ID: 3009666
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
    Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
    Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy with CCNU (NSC-79037),hexamethylmelamine (NSC-13875) and methotrexate (NSC-740) in advanced bronchogenic carcinoma.
    DiBella NJ; Nelson RA; Norgard MJ
    Oncology; 1975; 32(2):82-5. PubMed ID: 815858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC No. 409962) with amphotericin B in bronchogenic carcinoma.
    Presant CA; Hillinger S; Klahr C
    Cancer; 1980 Jan; 45(1):6-10. PubMed ID: 6243243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
    Sampi K; Kaneko Y; Maseki N; Kumai R; Sakurai M; Hattori M
    Gan To Kagaku Ryoho; 1985 Jul; 12(7):1453-7. PubMed ID: 4015120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II studies of methyl glyoxal bis-guanylhydrazone (NSC 32946) in carcinoma of the colon and lung.
    Killen JY; Mitchell EP; Hoth DF; Willis LL; Gullo JJ; Smith FP; Schein PS; Woolley PV
    Cancer; 1982 Oct; 50(7):1258-61. PubMed ID: 7104970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. cis-Dichlorodiammineplatinum (II) in small cell anaplastic bronchogenic carcinoma: a phase II study.
    Dombernowsky P; Sörenson S; Aisner J; Hansen HH
    Cancer Treat Rep; 1979 Apr; 63(4):543-5. PubMed ID: 221119
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination of surgery and polychemotherapy for cure in early small-cell bronchial carcinoma.
    Karrer K; Denck H; Obermair H; Pridun N; Zwintz E
    Bull Cancer; 1982; 69(1):94-7. PubMed ID: 6280796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
    Rowinsky EK; Adjei A; Donehower RC; Gore SD; Jones RJ; Burke PJ; Cheng YC; Grochow LB; Kaufmann SH
    J Clin Oncol; 1994 Oct; 12(10):2193-203. PubMed ID: 7931489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Benefits of cisplatin-based polychemotherapy in non-small cell bronchogenic carcinoma. Kyushu Lung Cancer Chemotherapy Study Group].
    Ohta M; Hara N; Ichikawa Y; Kanda T; Shima K; Tamura K; Hokama M
    Gan To Kagaku Ryoho; 1988 Jun; 15(6):1901-8. PubMed ID: 2454615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial of vindesine, etoposide, and cisplatin in patients with previously treated, advanced-stage, non-small cell bronchogenic carcinoma.
    Albain KS; Bitran JD; Golomb HM; Hoffman PC; DeMeester TR; Skosey C; Noble S; Blough RR
    Cancer Treat Rep; 1984 Feb; 68(2):413-5. PubMed ID: 6538114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
    Kantarjian HM; Gandhi V; Kozuch P; Faderl S; Giles F; Cortes J; O'Brien S; Ibrahim N; Khuri F; Du M; Rios MB; Jeha S; McLaughlin P; Plunkett W; Keating M
    J Clin Oncol; 2003 Mar; 21(6):1167-73. PubMed ID: 12637486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.
    Cohen MH; Broder LE; Fossieck BE; Ihde DC; Minna JD
    Cancer Treat Rep; 1977; 61(3):489-90. PubMed ID: 194694
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.